Skip to content

Clinical study of different concentration ropivacaine in intercostal nerve block in single-port thoracoscopic lobectomy

Clinical study of different concentration ropivacaine in intercostal nerve block in single-port thoracoscopic lobectomy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057739
Enrollment
Unknown
Registered
2022-03-16
Start date
2022-03-10
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

control group:normal saline intercostal nerve block
ropivacaine group 1:2% ropivacaine intercostal nerve block
ropivacaine group 2:3% ropivacaine intercostal nerve block
ropivacaine group 3:4% ropivacaine intercostal nerve block

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective single-hole thoracoscopic lobectomy in our hospital during 2021.7-2022.6; 2. Aged 40-75 years; 3. ASA: Grade I-III; 4. Weight 40-90kg.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to regional block technique (allergy to local anesthetic, infection around the puncture site and coagulation disorder); 2. Alcohol or drug abuse; 3. Severe circulatory diseases (severe hypertension, bradycardia and other heart diseases); 4. Previous chronic pain; 5. Dysfunction associated with inability to accurately participate in postoperative analgesia evaluation; 6. Active digestive tract ulcers or bleeding; 7. Failure to sign informed consent.

Design outcomes

Primary

MeasureTime frame
First press time of analgesia pump;

Secondary

MeasureTime frame
Pain scores at rest and during movement;Number of analgesic pump compressions;Recovery quality score;The amount of remedial drugs used after surgery;Postoperative hospital stay;Postoperative adverse reactions;Intraoperative anesthetic drugs, vasoactive drug dosage and infusion amount;Operation time;Interoperative adverse events;Haemodynamics;Anesthesia time;

Countries

China

Contacts

Public ContactXu Guanghong

First Affiliated Hospital of Anhui Medical University

xuguanghong2004@163.com+86 13856949535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026